Showing results (31-40 of 143) with videos related to
Sort By:
Pageof 15
Metabolism: Clinical and Experimental|August 21, 2013
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatmentTheodore P Ciaraldi, Vanita Aroda, Sunder R Mudaliar, et al.Plos One|July 26, 2016
Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 DiabetesTheodore P Ciaraldi, Alexander J Ryan, Sunder R Mudaliar, et al.Diabetes Care|March 19, 2016
Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 DiabetesAnne L Peters, Robert R Henry, Payal Thakkar, et al.Diabetes, Obesity & Metabolism|January 19, 2017
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot studyRobert R Henry, Paresh Dandona, Jeremy Pettus, et al.The Journal of Clinical Endocrinology and Metabolism|October 16, 2008
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistanceTheodore P Ciaraldi, Vanita Aroda, Sunder Mudaliar, et al.Endocrinology|June 16, 2007
Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cellsTheodore P Ciaraldi, Svetlana E Nikoulina, Rahil A Bandukwala, et al.Lancet (London, England)|June 12, 2009
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging studyRobert R Henry, A Michael Lincoff, Sunder Mudaliar, et al.Journal of Diabetes and Its Complications|March 18, 2014
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetesRobert R Henry, Julio Rosenstock, Douglas Logan, et al.Diabetes Care|April 12, 2014
Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?Alex M DePaoli, Linda S Higgins, Robert R Henry, et al.Diabetes|July 29, 2003
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reductionYoung-Bum Kim, Ko Kotani, Theodore P Ciaraldi, et al.Pageof 15